Abstracts tagged "Morning Stiffness"

Abstract Number: 0592 • ACR Convergence 2024
Sustained Improvements with Bimekizumab in Patient-Reported Symptoms of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Helena Marzo-Ortega¹, Philip Mease², Maxime Dougados³, Maureen Dubreuil⁴, Marina Magrey⁵, Martin Rudwaleit⁶, Maria Antonietta D'Agostino⁷, Christine de la Loge⁸, Ute Massow⁹, Vanessa Taieb¹⁰, Diana Voiniciuc¹¹ and Atul Deodhar¹², ¹NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ³Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁴Section of Rheumatology, Boston University School of Medicine, Boston, MA, ⁵Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH, ⁶University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁷Division of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Università Cattolica del Sacro Cuore, Rome, Italy, ⁸UCB Pharma, Brussels, Belgium, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰UCB Pharma, Colombes, France, ¹¹UCB Pharma, Slough, United Kingdom, ¹²Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: In the phase 3 studies, BE MOBILE 1 and 2, bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to…
Abstract Number: 1326 • ACR Convergence 2024
Which Biomarkers Indicate Imminent Progression to Inflammatory Arthritis in High Risk CCP Positive Persons?
Laurence Duquenne¹, Didem Sahin Eroglu², Jianhua Wu³, Kate Harnden¹, Andrea Di Matteo⁴, Lucy Elizabeth Thornton⁵, Rahaymin Chowdhury⁵, Leticia Garcia-Montoya¹, Kulveer Mankia⁶ and Paul Emery⁶, ¹1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, United Kingdom, ²1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Ankara, Turkey, ³1. University of Leeds, Leeds Institute for Data Analytics, Leeds, United Kingdom 2.Wolfson Institute of Population Health/Queen Mary University of London, UK, Leeds, ⁴1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Jesi, Italy, ⁵1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, ⁶University of Leeds, Leeds, United Kingdom
Background/Purpose: A risk stratification model proposed a simple score using 4 biomarkers to identify those at high risk of developing inflammatory arthritis (IA) in primary…
Abstract Number: 2596 • ACR Convergence 2024
Clock Gene Bmal1 Contributes to Inflammation via Phosphorylation of NF-κB/p65 in RA-FLS
Hikari Tsukamoto¹, Kenta Kaneshiro¹, Kohsuke Yoshida¹, Koji Tateishi², Yasuhiro Terashima², Nao Shibanuma³, Yoshitada Sakai⁴ and Akira Hashiramoto¹, ¹Kobe University Graduate School of Health Sciences, Kobe, Hyogo, Japan, ²Hakuhokai Kakogawa Hospital, Kakogawa, Hyogo, Japan, ³Kobe Kaisei Hospital, Kobe, Hyogo, Japan, ⁴Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
Background/Purpose: Inflammatory cytokines such as TNF-α, IL-6, and IFN-γ show their peaks at midnight in sera of patients with rheumatoid arthritis (RA), which is thought…
Abstract Number: 0011 • ACR Convergence 2023
Clock Gene Bmal1 Promotes Transcriptional Activity of NF-κB to Regulate Production of Inflammatory Mediators in RA-FLS
Hikari Tsukamoto¹, Kenta Kaneshiro², Kohsuke Yoshida¹, Koji Tateishi³, Yasuhiro Terashima³, Nao Shibanuma⁴, Yoshitada Sakai⁵ and Akira Hashiramoto¹, ¹Kobe University Graduate School of Health Sciences, Kobe, Japan, ²Kobe University Graduate School of Health Sciences, Osaka, Japan, ³Kohnan Kakogawa Hospital, Kakogawa, Japan, ⁴Kobe Kaisei Hospital, Kobe, Japan, ⁵Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Rheumatoid arthritis (RA), an autoimmune polyarthritis characterized by 'tumor-like' proliferation of RA fibroblast-like synovial cells (RA-FLS), has characteristic symptoms such as "morning stiffness of…
Abstract Number: 0510 • ACR Convergence 2023
Bimekizumab Treatment Improved Key Patient-Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain, Fatigue, and Morning Stiffness: 52-Week Results from Two Phase 3 Studies
Philip J. Mease¹, Maxime Dougados², Maureen Dubreuil³, Marina Nighat Magrey⁴, Helena Marzo-Ortega⁵, Martin Rudwaleit⁶, Christine de la Loge⁷, Carmen Fleurinck⁸, Ute Massow⁹, Vanessa Taieb¹⁰ and Atul Deodhar¹¹, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ²Department of Rheumatology, Hôpital Cochin, University of Paris Cité, Paris, France, ³Department of Rheumatology, Boston University School of Medicine, Milton, MA, ⁴Case Western Reserve University, University Hospitals, Cleveland, OH, ⁵NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁶University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Oosterzele, Belgium, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰UCB Pharma, Colombes, France, ¹¹Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. In the phase 3 studies BE MOBILE 1 and…
Abstract Number: 0721 • ACR Convergence 2023
Characterization of Numeric Rating Scales for Symptom Assessment in Polymyalgia Rheumatica
Tonya K Marmon¹, Jason C Cole², Claire Owen³, Sarah Mackie⁴ and David Katz⁵, ¹Marmon Biostatistics, Seattle, WA, ²P3 Research Consulting, Torrance, CA, ³Austin Health, Malvern East, Australia, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Sparrow Pharmaceuticals, Portland, OR
Background/Purpose: Pain, stiffness, and fatigue have been defined as core assessment domains in polymyalgia rheumatica (PMR) by the OMERACT PMR Working Group (PMRWG). Patient partners…
Abstract Number: 2211 • ACR Convergence 2023
A Two-year Comparison of Back Pain and Morning Stiffness in Axial Spondyloarthritis and Non-axial Spondyloarthritis Chronic Back Pain Patients in the Spondyloarthritis Caught Early (SPACE) Cohort
Ana Bento da Silva¹, Miranda Van Lunteren², Mary Lucy marques³, Karen Fagerli⁴, Sofia Ramiro⁵, Désirée van der Heijde⁵ and Floris Van Gaalen², ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, ³Leiden University Medical Center; Centro Hospitalar e Universitário de Coimbra (Department of Rheumatology), Coimbra, Portugal, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Treatment of axial spondyloarthritis (axSpA) has been shown to improve symptoms of the disease such as back pain (BP) and morning stiffness (MS). As…
Abstract Number: 0374 • ACR Convergence 2022
The BASDAI Index During Pregnancy
Olga Krichevskaya, Tatiana Dubinina, Ekaterina Ilinih, Svetlana Glukhova, Anastasia Demina and Irina Andrianova, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
Background/Purpose: During pregnancy, BASDAI may reflect not only the activity of ankylosing spondylitis (AS), but also back pain and fatigue, that are associated with the…
Abstract Number: 1491 • ACR Convergence 2022
Clinically Relevant Differences in the Mobility of Patients with Axial Spondyloarthritis Related to Daytime of Performance
David Kiefer¹, Juergen Braun¹, Lucia Schneider¹, Niklas Kolle¹, Uta Kiltz¹, Ioana Andreica², Philipp Sewerin¹, Bjoern Buehring³, susanne herbold¹ and Xenofon Baraliakos⁴, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ³Bergisches Rheuma-Zentrum, Velbert, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Patients with axial spondyloarthritis (axSpA) often experience impairments of spinal mobility and physical function due to inflammation and structural damage. Back pain and morning…
Abstract Number: 1196 • ACR Convergence 2021
Morning Stiffness Already Associates with Systemic Inflammation and Subclinical Joint Inflammation in the Pre-RA Phase of Arthralgia
Doortje Krijbolder¹, Fenne Wouters¹, Elise van Mulligen² and Annette H.M van der Helm-van Mil¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Morning stiffness (MS) is characteristic for Rheumatoid Arthritis (RA) and associates with markers of systemic and local inflammation in RA-patients. In patients with arthralgia,…
Abstract Number: 0560 • ACR Convergence 2021
Effectiveness, Safety, Quality of Life and Patient Satisfaction with Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: Second Interim Analysis of a German Non-Interventional, Prospective, Multi-Center Study
Klaus Krüger¹, Frank Behrens², Ulrich Prothmann³, Thilo Klopsch⁴, Lisa Blindzellner⁵, Olaf Behmer⁵, Jürgen Jobst⁵, Pascal Klaus⁵, Thomas Meng⁵ and Peter-Andreas Löschmann⁵, ¹Rheumatological Practice Center, Munich, Germany, ²CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine & Pharmacology, Goethe University Hospital, Frankfurt, Germany, ³Knappschaftsklinikum Saar, Püttlingen, Germany, ⁴Rheumatological Practice, Neubrandenburg, Germany, ⁵Pfizer Pharma GmbH, Berlin, Germany
Background/Purpose: Tofacitinib is a Janus kinase inhibitor, which is orally applied and is approved for rheumatoid arthritis among other indications. ESCALATE-RA is the first prospective,…
Abstract Number: 1011 • ACR Convergence 2020
Effectiveness, Safety and Quality of Life with Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: First Interim Results from a German Non-Interventional, Prospective, Multi-Center Study
Frank Behrens¹, Ulrich Prothmann², Thilo Klopsch³, Ann-Dörthe Holst⁴, Lisa Blindzellner⁵, Olaf Behmer⁵, Pascal Klaus⁵, Thomas Meng⁵ and Peter-Andreas Löschmann⁵, ¹CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ²Knappschaftsklinikum Saar, Püttlingen, Saarland, Germany, ³Rheumatological Practice, Neubrandenburg, Mecklenburg-Vorpommern, Germany, ⁴Specialist Practice for General Medicine incl. Rheumatology and Acupuncture, Ludwigslust, Mecklenburg-Vorpommern, Germany, ⁵Pfizer Pharma GmbH, Berlin, Berlin, Germany
Background/Purpose: Tofacitinib is an orally applied Janus kinase inhibitor, which is approved for rheumatoid arthritis (RA) treatment in the USA since 2012, so that ‘real…
Abstract Number: 1340 • ACR Convergence 2020
Secukinumab Improves Pain, Morning Stiffness, Fatigue and Physical Function in Tumor Necrosis Factor Inhibitor-Naïve Patients with Non-Radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study
Helena Marzo-Ortega¹, Atul Deodhar², Ricardo Blanco³, Hideto Kameda⁴, Alan Kivitz⁵, Denis Poddubnyy⁶, Marina Magrey⁷, Jianyuan Wang⁸, Sibylle Haemmerle⁸, Abhijit Shete⁸ and Juergen Braun⁹, ¹The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ²Oregon Health & Science University, Portland, OR, ³Hospital University Marqués de Valdecilla, Santander, Spain, ⁴Toho University, Tokyo, Japan, ⁵Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ⁶Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁷Case Western Reserve University School of Medicine, Cleveland, OH, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Rheumazentrum Ruhrgebiet and Ruhr-University, 44649 Herne, Germany
Background/Purpose: Patients with non-radiographic axial spondyloarthritis (nr-axSpA) suffer from comparable disease burden to patients with ankylosing spondylitis/radiographic axSpA (AS/r-axSpA), including inflammatory back pain, morning stiffness,…
Abstract Number: 1847 • ACR Convergence 2020
Delayed and Immediate Release Prednisone Decrease Fatigue Comparably in Patients with Systemic Lupus Erythematosus
Hope Rainey¹, Kristy Bell¹, Violeta Rus², Daniel Wallace³, Claire Dykas¹, Mary Mora¹, Maggy Comberg¹ and Peter Lipsky¹, ¹AMPEL BioSolutions LLC., Charlottesville, VA, ²University of Maryland School of Medicine, Baltimore, MD, ³Cedars-Sinai Medical Center/UCLA, Los Angeles, CA
Background/Purpose: Morning stiffness and fatigue are common symptoms in patients with SLE. Increased cytokines and disturbed sleep patterns may contribute to morning symptoms and fatigue…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].